Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Page 1
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
Hoyt JA, Cozzi E, D'Alessio DA, Thompson CC, Aroda VR. Hoyt JA, et al. Among authors: d alessio da. Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15533. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38433708 Review.
Affecting 5%-10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long-term therapies to reduce blood glucose, an approach that can mitigate the vascular complications. ...
Affecting 5%-10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. …
An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug.
Ozer I, Slezak A, Sirohi P, Li X, Zakharov N, Yao Y, Everitt JI, Spasojevic I, Craig SL, Collier JH, Campbell JE, D'Alessio DA, Chilkoti A. Ozer I, et al. Among authors: d alessio da. Biomaterials. 2023 Mar;294:121985. doi: 10.1016/j.biomaterials.2022.121985. Epub 2023 Jan 3. Biomaterials. 2023. PMID: 36630826 Free PMC article.
The injectable depot-forming exendin-POEGMA conjugate did not elicit an immune response against the polymer, so that it remained effective and safe for long-term management of type 2 diabetes upon chronic administration. In contrast, the PEG conjugate induced an anti-PEG i …
The injectable depot-forming exendin-POEGMA conjugate did not elicit an immune response against the polymer, so that it remained effective a …
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. Urva S, et al. Among authors: d alessio da. Lancet. 2022 Nov 26;400(10366):1869-1881. doi: 10.1016/S0140-6736(22)02033-5. Epub 2022 Oct 27. Lancet. 2022. PMID: 36354040 Clinical Trial.
BACKGROUND: Treating hyperglycaemia and obesity in individuals with type 2 diabetes using multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic polype …
BACKGROUND: Treating hyperglycaemia and obesity in individuals with type 2 diabetes using multi-receptor agonists can improve short-term …
High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
Mul JD, Begg DP, Barrera JG, Li B, Matter EK, D'Alessio DA, Woods SC, Seeley RJ, Sandoval DA. Mul JD, et al. Among authors: d alessio da. Am J Physiol Regul Integr Comp Physiol. 2013 Jul 1;305(1):R68-77. doi: 10.1152/ajpregu.00588.2012. Epub 2013 Apr 24. Am J Physiol Regul Integr Comp Physiol. 2013. PMID: 23616105 Free PMC article.
Glucagon-like peptide 1 (GLP-1) is an important gastrointestinal signal that modulates both short- and long-term energy balance and is integral in maintenance of glucose homeostasis. ...
Glucagon-like peptide 1 (GLP-1) is an important gastrointestinal signal that modulates both short- and long-term energy balance and i …
GLP-1 and energy balance: an integrated model of short-term and long-term control.
Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. Barrera JG, et al. Among authors: d alessio da. Nat Rev Endocrinol. 2011 Jun 7;7(9):507-16. doi: 10.1038/nrendo.2011.77. Nat Rev Endocrinol. 2011. PMID: 21647189 Free PMC article. Review.
Specifically, we consider contributions of both central and peripheral GLP-1 and propose an integrated model of short-term and long-term control of energy balance. Finally, we discuss this model with respect to current GLP-1-based therapies and suggest ongoing resea …
Specifically, we consider contributions of both central and peripheral GLP-1 and propose an integrated model of short-term and long- …
Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function.
Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ. Barrera JG, et al. Among authors: d alessio da. J Neurosci. 2011 Mar 9;31(10):3904-13. doi: 10.1523/JNEUROSCI.2212-10.2011. J Neurosci. 2011. PMID: 21389245 Free PMC article.
Collectively, these data provide the strongest evidence to date that CNS GLP-1 plays a physiologic role in the long-term regulation of energy balance. Moreover, they suggest that this role is distinct from that of circulating GLP-1 as a short-term satiation signal. …
Collectively, these data provide the strongest evidence to date that CNS GLP-1 plays a physiologic role in the long-term regulation o …
Benefits of high-protein weight loss diets: enough evidence for practice?
Brehm BJ, D'Alessio DA. Brehm BJ, et al. Among authors: d alessio da. Curr Opin Endocrinol Diabetes Obes. 2008 Oct;15(5):416-21. doi: 10.1097/MED.0b013e328308dc13. Curr Opin Endocrinol Diabetes Obes. 2008. PMID: 18769212 Review.
Evidence that chronic high-protein intake affects glucose metabolism is inconclusive at present. Further study of the long-term safety of diets with varying amounts of protein is warranted. ...Diets moderately increased in protein and modestly restricted in carbohydrate an …
Evidence that chronic high-protein intake affects glucose metabolism is inconclusive at present. Further study of the long-term safet …
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.
Salehi M, Aulinger BA, D'Alessio DA. Salehi M, et al. Among authors: d alessio da. Endocr Rev. 2008 May;29(3):367-79. doi: 10.1210/er.2007-0031. Epub 2008 Feb 21. Endocr Rev. 2008. PMID: 18292465 Free PMC article. Review.
Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed …
Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by exp …
Voluntary consumption of ethyl oleate reduces food intake and body weight in rats.
Kemp CJ, D'Alessio DA, Scott RO, Kelm GR, Meller ST, Barrera JG, Seeley RJ, Clegg DJ, Benoit SC. Kemp CJ, et al. Among authors: d alessio da. Physiol Behav. 2008 Mar 18;93(4-5):912-8. doi: 10.1016/j.physbeh.2007.12.008. Epub 2007 Dec 23. Physiol Behav. 2008. PMID: 18234242 Free PMC article.
These data indicate that voluntary access to EO promoted short-term satiety, compared to SO diet, and that these effects contributed to an important and novel attenuated weight gain in EO-fed animals....
These data indicate that voluntary access to EO promoted short-term satiety, compared to SO diet, and that these effects contributed …
Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck PE, Hudson JI. McElroy SL, et al. Among authors: d alessio da. J Clin Psychiatry. 2006 Dec;67(12):1897-906. doi: 10.4088/jcp.v67n1209. J Clin Psychiatry. 2006. PMID: 17194267 Clinical Trial.
CONCLUSION: Zonisamide was efficacious, but not well tolerated, in the short-term treatment of BED associated with obesity. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00221442....
CONCLUSION: Zonisamide was efficacious, but not well tolerated, in the short-term treatment of BED associated with obesity. CLINICAL …
15 results